LUND, Sweden--(BUSINESS WIRE)--Researchers at the University of Utah, Salt Lake City, under the direction of professor Guido Tricot, will present data involving BI-505 at the annual meeting of American Society of Hematology, which takes place in San Diego, December 10-13, 2011. The abstract will be discussed during an oral session on Sunday, December 11, 2011.
The abstract can be retrieved at www.hematology.org under the Abstract section.
Abstract #2914, The effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells. Session: 652, Myeloma – Pathophysiology and Pre-Clinical Studies. Sunday, December 11, 2011, 6:00 PM-8:00 PM.
A poster will be accessible at the BioInvent home page after the presentation on December 11, 2011.
-- END --
To the editors:
About BI-505
BI-505 is a fully human, monoclonal antibody
developed from BioInvent’s proprietary screening platform FIRST™, a
function first approach to antibody drug discovery, which in its turn
builds on BioInvent’s extensive n-CoDeR® library. BI-505 binds to the
cell-surface protein ICAM-1 (Inter-Cellular Adhesion Molecule-1), which
has been shown to be overexpressed in multiple myeloma cell lines and
primary patient myeloma cells. BioInvent has shown in animal models for
multiple myeloma that BI-505 kills tumour cells through induction of
both programmed cell death and Fc gamma receptor dependent anti-tumour
immunity. BI-505 is currently being investigated in a phase I clinical
trial involving approximately 35 patients at clinical centres both in
the US and EU.
About multiple myeloma
Multiple myeloma is a type of cancer
formed by malignant plasma cells. Normal plasma cells, also called B
cells, are mostly found in the bone marrow and are important parts of
the innate immune system. It is expected that 20,520 new cases of
multiple myeloma will be diagnosed in the US in 2011, making it the
second most common haematological cancer. The 5-year relative survival
rate is around 40 per cent (www.cancer.org).
About BioInvent
BioInvent International AB, listed on the
NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company
that focuses on developing antibody drugs. The Company currently has
four clinical development projects within the areas of thrombosis,
cancer and atherosclerosis. The Company has signed various strategic
alliances to strengthen the product pipeline and increase the likelihood
of success. These partners include Genentech, Human Genome Sciences,
Roche and ThromboGenics.
The company’s competitive position is underpinned by its patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com.
Legal disclaimer
This press release contains
statements about the future, consisting of subjective assumptions and
forecasts for future scenarios. Predictions for the future only apply as
of the date they are made and are, by their very nature, in the same way
as research and development work in the biotech segment, associated with
risk and uncertainty. With this in mind, the actual outcome may deviate
significantly from the scenarios described in this press release.
Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 2 December, 2011.